| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers S > Headlines for Sunesis Pharmaceuticals, Inc. > News item |
Sunesis demonstrates SNS-032 benefits at cancer research meeting
By Lisa Kerner
Erie, Pa., April 4 - Sunesis Pharmaceuticals, Inc. highlighted the mechanism of action for SNS-032 and provided new insights into its potential benefits for the treatment of various cancers at the Annual Meeting of the American Association for Cancer Research.
The company presented data from in vitro studies of SNS-032 demonstrating that the compound is a potent, highly selective inhibitor of Cyclin Dependent Kinases (CDK) 2, 7 and 9, which play a role in cell-cycle progression and transcriptional regulation.
Sunesis presented the data on a poster titled "SNS-032 is a potent and selective inhibitor of CDK 2, 7 and 9 and induces cell death by inhibiting cell cycle progression and the expression of antiapoptotic proteins," according to a news release.
SNS-032 is in a phase 1/2 clinical study to identify the maximum-tolerated dose, examine its safety and preliminary evidence of antitumor activity in patients with advanced solid tumor malignancies, including lung cancer, breast cancer or melanoma.
Cells treated with SNS-032 demonstrate cell-cycle arrest and apoptosis (programmed cell death). Additionally, SNS-032 acts to deplete cells of MCL-1, a protein associated with cancer cell survival, Sunesis said.
"SNS-032's ability to both target cell proliferation and to circumvent the mechanism by which certain cancers avoid apoptosis underline SNS-032's potential to be a useful treatment of a variety of cancer types," senior vice president, research and development Daniel C. Adelman said in the release.
Sunesis is a clinical-stage biopharmaceutical company that based in South San Francisco.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.